Spinal Stenosis - Pipeline Review, H2 2012

Global Markets Direct, November 2012, Pages: 32

Spinal Stenosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Spinal Stenosis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Spinal Stenosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Stenosis. Spinal Stenosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Spinal Stenosis.
- A review of the Spinal Stenosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Spinal Stenosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Spinal Stenosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Spinal Stenosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Spinal Stenosis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Spinal Stenosis 7
Spinal Stenosis Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Spinal Stenosis Therapeutics – Products under Development by Companies 13
Companies Involved in Spinal Stenosis Therapeutics Development 14
Kaken Pharmaceutical Co.,Ltd. 14
Mesoblast Ltd 15
LTT Bio-Pharma Co., Ltd. 16
Sucampo Pharmaceuticals, Inc. 17
Spinal Stenosis – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
LT-0101 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
SPI-017 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ecraprost - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
beraprost sodium SR - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
SPI-3608 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
NeoFuse - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Spinal Stenosis Therapeutics – Drug Profile Updates 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables
Number of Products Under Development for Spinal Stenosis, H2 2012 7
Products under Development for Spinal Stenosis – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Mid Clinical Stage Development, H2 2012 10
Comparative Analysis by Early Clinical Stage Development, H2 2012 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Kaken Pharmaceutical Co.,Ltd., H2 2012 14
Mesoblast Ltd, H2 2012 15
LTT Bio-Pharma Co., Ltd., H2 2012 16
Sucampo Pharmaceuticals, Inc., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Spinal Stenosis Therapeutics – Drug Profile Updates 30

List of Figures
Number of Products under Development for Spinal Stenosis, H2 2012 7
Products under Development for Spinal Stenosis – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Mid Clinical Stage Products, H2 2012 10
Early Clinical Stage Products, H2 2012 11
Discovery and Pre-Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Customers who bought this item also bought

• Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Osteoarthritis - Pipeline Review, H2 2012
• Epilepsy - Pipeline Review, H2 2012
• Type 2 Diabetes - Pipeline Review, H2 2012
• Autoimmune Disorders - Pipeline Review, H2 2012